Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Intrinsic Value
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. [ Read More ]
The intrinsic value of one
Shenzhen New Industries Biomedical Engineering Co Ltd
stock under the Base Case scenario is
75.63
CNY.
Compared to the current market price of 68.23 CNY,
Shenzhen New Industries Biomedical Engineering Co Ltd
is
Undervalued by 10%.
Shenzhen New Industries Biomedical Engineering Co Ltd's market capitalization is 53.6B CNY.
Shenzhen New Industries Biomedical Engineering Co Ltd stock price is 68.23 CNY.
Shenzhen New Industries Biomedical Engineering Co Ltd stock price (68.23 CNY) is 10% less than its Intrinsic Value (75.63 CNY).
Shenzhen New Industries Biomedical Engineering Co Ltd stock price (68.23 CNY) is 20% less than its DCF Value (85.38 CNY). Open DCF Valuation
Shenzhen New Industries Biomedical Engineering Co Ltd stock (65.88 CNY) is 3% less than its price (68.23 CNY). Open Relative Valuation
Shenzhen New Industries Biomedical Engineering Co Ltd has upside potential of 27% compared to the average analyst price target.
Open Wall St Estimates
Shenzhen New Industries Biomedical Engineering Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 24% to 24%.
Shenzhen New Industries Biomedical Engineering Co Ltd's Revenue has grown by an exceptional 29% over the past 12 months.
Shenzhen New Industries Biomedical Engineering Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 24%.
Shenzhen New Industries Biomedical Engineering Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 49% to 38%.
Shenzhen New Industries Biomedical Engineering Co Ltd's Revenue has been growing by an exceptional 21% per year for the last 3 years.
Shenzhen New Industries Biomedical Engineering Co Ltd has positive three-year average ROE (Return on Equity): 22%. The company is efficient at transforming stockholders' equity into net income.
Shenzhen New Industries Biomedical Engineering Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 38%.
Shenzhen New Industries Biomedical Engineering Co Ltd has positive Operating Income for the last twelve months.
Shenzhen New Industries Biomedical Engineering Co Ltd has positive Net Income for the last twelve months.
Shenzhen New Industries Biomedical Engineering Co Ltd has positive Free Cash Flow for the last twelve months.
Shenzhen New Industries Biomedical Engineering Co Ltd has positive Gross Profit for the last twelve months.
Shenzhen New Industries Biomedical Engineering Co Ltd has very high three-year average ROIC (Return on Invested Capital): 42%. The company is very efficient at using invested capital to generate operating income.
Shenzhen New Industries Biomedical Engineering Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.
Shenzhen New Industries Biomedical Engineering Co Ltd's short-term assets (5B CNY) exceed its short-term liabilties (591m CNY).
Shenzhen New Industries Biomedical Engineering Co Ltd's long-term assets (8B CNY) exceed its long-term liabilties (678m CNY).
Shenzhen New Industries Biomedical Engineering Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (3B CNY) than debt (3m CNY).
Shenzhen New Industries Biomedical Engineering Co Ltd's Altman Z-Score is very high and is equal to 56.63.
Valuation Backtest
Shenzhen New Industries Biomedical Engineering Co Ltd
Run backtest to discover the historical profit from buying and selling
Shenzhen New Industries Biomedical Engineering Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Shenzhen New Industries Biomedical Engineering Co Ltd
Balance Sheet Decomposition
Shenzhen New Industries Biomedical Engineering Co Ltd
| Current Assets | 5.1B |
| Cash & Short-Term Investments | 3.4B |
| Receivables | 712.4m |
| Other Current Assets | 944m |
| Non-Current Assets | 3.2B |
| Long-Term Investments | 1.2B |
| PP&E | 1.4B |
| Intangibles | 169.5m |
| Other Non-Current Assets | 383.8m |
| Current Liabilities | 591.5m |
| Accounts Payable | 127m |
| Accrued Liabilities | 185m |
| Other Current Liabilities | 279.5m |
| Non-Current Liabilities | 86.6m |
| Long-Term Debt | 3.5m |
| Other Non-Current Liabilities | 83.1m |
Earnings Waterfall
Shenzhen New Industries Biomedical Engineering Co Ltd
|
Revenue
|
3.9B
CNY
|
|
Cost of Revenue
|
-1.1B
CNY
|
|
Gross Profit
|
2.9B
CNY
|
|
Operating Expenses
|
-1.1B
CNY
|
|
Operating Income
|
1.8B
CNY
|
|
Other Expenses
|
-130.9m
CNY
|
|
Net Income
|
1.7B
CNY
|
Free Cash Flow Analysis
Shenzhen New Industries Biomedical Engineering Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Shenzhen New Industries Biomedical Engineering Co Ltd's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Score
Shenzhen New Industries Biomedical Engineering Co Ltd's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shenzhen New Industries Biomedical Engineering Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Shenzhen New Industries Biomedical Engineering Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shenzhen New Industries Biomedical Engineering Co Ltd
According to Wall Street analysts, the average 1-year price target for
Shenzhen New Industries Biomedical Engineering Co Ltd
is 86.91 CNY
with a low forecast of 64.64 CNY and a high forecast of 110.48 CNY.
Shareholder Return
Price
Shenzhen New Industries Biomedical Engineering Co Ltd
| Average Annual Return | 63.12% |
| Standard Deviation of Annual Returns | 126.48% |
| Max Drawdown | -69% |
| Market Capitalization | 53.6B CNY |
| Shares Outstanding | 785 719 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Shenzhen New Industries Biomedical Engineering Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The company is headquartered in Shenzhen, Guangdong and currently employs 2,298 full-time employees. The company went IPO on 2020-05-12. The firm operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The firm sells its products both in domestic and international markets, including Asia, Europe, America and Africa.
Contact
IPO
Employees
Officers
The intrinsic value of one
Shenzhen New Industries Biomedical Engineering Co Ltd
stock under the Base Case scenario is
75.63
CNY.
Compared to the current market price of 68.23 CNY,
Shenzhen New Industries Biomedical Engineering Co Ltd
is
Undervalued by 10%.
You don't have any saved screeners yet
